Pedro Dal Lago | Universidade Federal de Ciências da Saúde de Porto Alegre (original) (raw)

Papers by Pedro Dal Lago

Autonomic Neuroscience: Basic and Clinical, Nov 1, 2015

Medial prefrontal cortex (MPFC) NMDA receptor/Nitric Oxide (NO) pathway enhances the baroreflex a... more Medial prefrontal cortex (MPFC) NMDA receptor/Nitric Oxide (NO) pathway enhances the baroreflex activity. CB1 receptors decrease glutamate release and negatively modulate the baroreflex response in the MPFC. Therefore the aim of this study is to investigate if the MPFC CB1 receptors modulate the baroreflex by influencing the NMDA receptor/NO pathway. Male Wistar rats had stainless steel guide cannulae implanted into the MPFC and baroreflex was activated by intravenous infusion of phenylephrine or sodium nitroprusside. A second catheter was implanted into the femoral artery for cardiovascular measurements. The CB1 receptor antagonist, AM251 (100 nmol/200 nL), injected into the MPFC increased both bradycardic (F (2,14) = 9.52; p b 0.05, n = 5) and tachycardic (F (2,14) = 4.15; p b 0.05, n = 5) reflex responses. This effect was prevented by MPFC treatment with ineffective doses of the NMDA receptor antagonist, AP7 (0.4 nmol/200 nL; bradycardia: F (2,17) = 0.66; p N 0.05, and tachycardia: F (2,17) = 0.33; p N 0.05, n = 6), the neuronal NO synthase inhibitor, n-propyl (8 pmol/ 200 nL; bradycardia: F (2,17) = 0.34; p N 0.05, and tachycardia: F (2,17) = 0.26; p N 0.05, n = 6); the extracellular NO scavenger, c-PTIO (0.2 nmol/200 nL; bradycardia: F (2,17) = 0.40; p N 0.05, and tachycardia: F (2,17) = 1.44; p N 0.05, n = 6); the guanilate cyclase inhibitor, ODQ (0.2 nmol/200 nL; bradycardia: F (2,17) = 0.11; p N 0.05, and tachycardia: F (2,17) = 0.28; p N 0.05, n = 6), previously to the microinjection of AM251 in the same dose. In conclusion, the results show that the MPFC CB1 receptors decrease the baroreflex activity by reducing the glutamate release and the NO production by the NMDA receptors.

Arquivos Brasileiros De Cardiologia, Aug 1, 2012

Patients with chronic heart failure (CHF) may have lower inspiratory muscle strength and enduranc... more Patients with chronic heart failure (CHF) may have lower inspiratory muscle strength and endurance, which may contribute to exercise intolerance. Inspiratory muscle training (IMT) can have beneficial effects on these patients. Thus, the aim of this study was to systematically review the effects of IMT compared to control groups (placebo-IMT or another intervention) in patients with CHF. A search of databases (MEDLINE, Cochrane CENTRAL and PEDro) and references of published studies, from 1960 to 2011, was conducted. Randomized trials comparing IMT to control groups in the treatment of patients with CHF were included. The GRADE approach was used to determine the quality of evidence for each outcome. Of 119 articles identified, 7 studies were included. IMT increased the distance walked in the six-minute walk test [69 m (95% CI: 7.21 to 130.79)] (very low evidence) and maximal static inspiratory pressure [23.36 cmH20 (95% CI: 11.71 to 35.02)] (low evidence) compared to control groups. However, IMT provides a significant improvement in peak oxygen consumption only in the studies that performed IMT for 12 weeks against no inspiratory load in patients with inspiratory muscle weakness [3.02 ml/kg/min-1 (95% CI: 0.43 to 5.61)]. IMT improves functional capacity and inspiratory muscle strength thereby deserving consideration as an additional intervention in patients with CHF. Larger and better-designed studies, however, are needed to clarify the potential benefit of IMT in this patient population.

Revista Brasileira De Fisioterapia, Apr 1, 2013

Background: Painful diabetic neuropathy (PDN) is a common complication of diabetes mellitus, and ... more Background: Painful diabetic neuropathy (PDN) is a common complication of diabetes mellitus, and pharmacological therapies are ineffective in many patients. Therefore, other treatment modalities should be considered, including electrical stimulation and electromagnetic fields. Objectives: The research objective was to evaluate the effect of treatment with electrical stimulation and electromagnetic fields on pain and sensitivity in patients with painful diabetic neuropathy compared with placebo or another intervention. Method: We searched the following electronic databases (from inception to April 2012): MEDLINE (accessed by PubMed), LILACS, Physiotherapy Evidence Database (PEDro), EMBASE and Cochrane CENTRAL. We included randomized trials that compared electrical stimulation or electromagnetic fields with control groups in which the objective was to assess pain and sensitivity in patients with PDN. Two reviewers independently extracted the data. A random-effects model was used for the main analysis. Results: The search retrieved 1336 articles, of which 12 studies were included. Reductions in the mean pain score were significantly greater in the TENS (transcutaneous electrical nerve stimulation) group than in the placebo group [-0.44 (95% CI:-0.79 to-0.09; I2: 0%)]. There was no improvement in pain relief when electromagnetic fields were compared with the control group [-0.69 (95% CI:-1.86 to 0.48; I2: 63%)]. Conclusions: We found that TENS improved pain relief in patients with diabetic neuropathy, while no such improvement was observed with the use of electromagnetic field treatment. Due to the methodological differences between the studies, a meta-analysis for the outcome of sensitivity could not be performed.

Revista Brasileira De Fisioterapia, Apr 1, 2013

Autonomic Neuroscience: Basic and Clinical, Nov 1, 2015

Arquivos Brasileiros De Cardiologia, Aug 1, 2012

Revista Brasileira De Fisioterapia, Apr 1, 2013